Novavax, Takeda partner on COVID vaccine in Japan

Friday, 07. August 2020 11:52

Novavax Inc. announced on Friday it struck a partnership with Takeda Pharmaceutical Company Limited on the development, manufacturing and commercialization of its coronavirus vaccine candidate in Japan.

Under the agreement, Novavax will provide Takeda with manufacturing technologies to make the vaccine and will receive payments when certain development and commercial milestones are achieved and a portion of proceeds from vaccine sales. "Takeda’s leading position in Japan, technical expertise, regulatory know-how and manufacturing capacity make the company an ideal partner to further expand the global availability of NVX‑CoV2373," Novavax CEO Stanley Erck stated.

Earlier this week, Novavax said its vaccine candidate showed promising results during early-stage clinical trials and noted it is aiming to have between 1 million and 2 million coronavirus vaccine doses by 2021.

Related Links: Takeda Pharmaceutical Company Ltd.
Breaking the News / NP